patritumab
medsir,daiichi sankyo
['patritumab', 'mbc', 'breast', 'medsir']
dr. ian krop from shares phase i data from the novel her3 adc patritumab deruxtecan which show durable efficacy in heavily pretreated her3-positive mbc. anti-tumor activity was seen across breast cancer subtypes and regardless her3 expression levels.
#asco22 
Bring your idea to life?? 
Creating successful IITs & optimizing drug development ?? 
Medica Scientia Innovation Research
 ????&????
https://t.co/yp3O5Lylqc